Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer

Tao Wei, Xiaoyu Zhang, Qi Zhang, Jiaqi Yang, Qi Chen, Jianxin Wang, Xiang Li, Junye Chen, Tao Ma, Guogang Li, Shunliang Gao, Jianying Lou, Risheng Que, Yi Wang, Xiaowei Dang, Lei Zheng, Tingbo Liang, Xueli Bai

Research output: Contribution to journalArticle

Abstract

The identification of circulating tumor cells (CTCs) relies on epithelial tumor cell markers. In the present study, we aimed to determine whether cell-surface vimentin could be a biomarker to isolate CTCs in pancreatic ductal adenocarcinoma (PDAC). Vimentin was identified as highly expressed on the surface of mesenchymal-phenotype pancreatic tumor cells. Vimentin + CTCs were detected in 76% of patients with PDAC (76/100) using CTCs enriched via a microfluidic assay. A cut-off value of two vimentin + CTCs distinguished patients with PDAC from healthy individuals. Combined vimentin + CTCs and Carbohydrate antigen 19–9 provided favorable diagnostic potency, with an area under the curve of 0.968. Vimentin + CTCs counts correlated with the change in tumor burden for patients undergoing resection. Significantly reduced CTC counts were observed after chemotherapy in subjects that responded to treatment. Preoperatively higher CTCs counts correlated with shortened recurrence-free survival. Taken together, vimentin + CTCs could be a reliable biomarker in pancreatic cancer. The enrichment of mesenchymal CTCs complements the strategy of capturing epithelial CTCs, allowing a more thorough interrogation of the biology and clinical significance of CTCs in PDAC.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalCancer Letters
Volume452
DOIs
StatePublished - Jun 28 2019

Fingerprint

Circulating Neoplastic Cells
Physiologic Monitoring
Vimentin
Pancreatic Neoplasms
Biomarkers
Therapeutics
Adenocarcinoma
Cell Count
Epithelial Cells
Microfluidics
Tumor Biomarkers
Tumor Burden
Area Under Curve

Keywords

  • Biomarker
  • CTCs
  • Epithelial-mesenchymal transition
  • Pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. / Wei, Tao; Zhang, Xiaoyu; Zhang, Qi; Yang, Jiaqi; Chen, Qi; Wang, Jianxin; Li, Xiang; Chen, Junye; Ma, Tao; Li, Guogang; Gao, Shunliang; Lou, Jianying; Que, Risheng; Wang, Yi; Dang, Xiaowei; Zheng, Lei; Liang, Tingbo; Bai, Xueli.

In: Cancer Letters, Vol. 452, 28.06.2019, p. 237-243.

Research output: Contribution to journalArticle

Wei, T, Zhang, X, Zhang, Q, Yang, J, Chen, Q, Wang, J, Li, X, Chen, J, Ma, T, Li, G, Gao, S, Lou, J, Que, R, Wang, Y, Dang, X, Zheng, L, Liang, T & Bai, X 2019, 'Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer', Cancer Letters, vol. 452, pp. 237-243. https://doi.org/10.1016/j.canlet.2019.03.009
Wei, Tao ; Zhang, Xiaoyu ; Zhang, Qi ; Yang, Jiaqi ; Chen, Qi ; Wang, Jianxin ; Li, Xiang ; Chen, Junye ; Ma, Tao ; Li, Guogang ; Gao, Shunliang ; Lou, Jianying ; Que, Risheng ; Wang, Yi ; Dang, Xiaowei ; Zheng, Lei ; Liang, Tingbo ; Bai, Xueli. / Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. In: Cancer Letters. 2019 ; Vol. 452. pp. 237-243.
@article{f34cbe8b72b3425ba9f468c50e765704,
title = "Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer",
abstract = "The identification of circulating tumor cells (CTCs) relies on epithelial tumor cell markers. In the present study, we aimed to determine whether cell-surface vimentin could be a biomarker to isolate CTCs in pancreatic ductal adenocarcinoma (PDAC). Vimentin was identified as highly expressed on the surface of mesenchymal-phenotype pancreatic tumor cells. Vimentin + CTCs were detected in 76{\%} of patients with PDAC (76/100) using CTCs enriched via a microfluidic assay. A cut-off value of two vimentin + CTCs distinguished patients with PDAC from healthy individuals. Combined vimentin + CTCs and Carbohydrate antigen 19–9 provided favorable diagnostic potency, with an area under the curve of 0.968. Vimentin + CTCs counts correlated with the change in tumor burden for patients undergoing resection. Significantly reduced CTC counts were observed after chemotherapy in subjects that responded to treatment. Preoperatively higher CTCs counts correlated with shortened recurrence-free survival. Taken together, vimentin + CTCs could be a reliable biomarker in pancreatic cancer. The enrichment of mesenchymal CTCs complements the strategy of capturing epithelial CTCs, allowing a more thorough interrogation of the biology and clinical significance of CTCs in PDAC.",
keywords = "Biomarker, CTCs, Epithelial-mesenchymal transition, Pancreatic ductal adenocarcinoma",
author = "Tao Wei and Xiaoyu Zhang and Qi Zhang and Jiaqi Yang and Qi Chen and Jianxin Wang and Xiang Li and Junye Chen and Tao Ma and Guogang Li and Shunliang Gao and Jianying Lou and Risheng Que and Yi Wang and Xiaowei Dang and Lei Zheng and Tingbo Liang and Xueli Bai",
year = "2019",
month = "6",
day = "28",
doi = "10.1016/j.canlet.2019.03.009",
language = "English (US)",
volume = "452",
pages = "237--243",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer

AU - Wei, Tao

AU - Zhang, Xiaoyu

AU - Zhang, Qi

AU - Yang, Jiaqi

AU - Chen, Qi

AU - Wang, Jianxin

AU - Li, Xiang

AU - Chen, Junye

AU - Ma, Tao

AU - Li, Guogang

AU - Gao, Shunliang

AU - Lou, Jianying

AU - Que, Risheng

AU - Wang, Yi

AU - Dang, Xiaowei

AU - Zheng, Lei

AU - Liang, Tingbo

AU - Bai, Xueli

PY - 2019/6/28

Y1 - 2019/6/28

N2 - The identification of circulating tumor cells (CTCs) relies on epithelial tumor cell markers. In the present study, we aimed to determine whether cell-surface vimentin could be a biomarker to isolate CTCs in pancreatic ductal adenocarcinoma (PDAC). Vimentin was identified as highly expressed on the surface of mesenchymal-phenotype pancreatic tumor cells. Vimentin + CTCs were detected in 76% of patients with PDAC (76/100) using CTCs enriched via a microfluidic assay. A cut-off value of two vimentin + CTCs distinguished patients with PDAC from healthy individuals. Combined vimentin + CTCs and Carbohydrate antigen 19–9 provided favorable diagnostic potency, with an area under the curve of 0.968. Vimentin + CTCs counts correlated with the change in tumor burden for patients undergoing resection. Significantly reduced CTC counts were observed after chemotherapy in subjects that responded to treatment. Preoperatively higher CTCs counts correlated with shortened recurrence-free survival. Taken together, vimentin + CTCs could be a reliable biomarker in pancreatic cancer. The enrichment of mesenchymal CTCs complements the strategy of capturing epithelial CTCs, allowing a more thorough interrogation of the biology and clinical significance of CTCs in PDAC.

AB - The identification of circulating tumor cells (CTCs) relies on epithelial tumor cell markers. In the present study, we aimed to determine whether cell-surface vimentin could be a biomarker to isolate CTCs in pancreatic ductal adenocarcinoma (PDAC). Vimentin was identified as highly expressed on the surface of mesenchymal-phenotype pancreatic tumor cells. Vimentin + CTCs were detected in 76% of patients with PDAC (76/100) using CTCs enriched via a microfluidic assay. A cut-off value of two vimentin + CTCs distinguished patients with PDAC from healthy individuals. Combined vimentin + CTCs and Carbohydrate antigen 19–9 provided favorable diagnostic potency, with an area under the curve of 0.968. Vimentin + CTCs counts correlated with the change in tumor burden for patients undergoing resection. Significantly reduced CTC counts were observed after chemotherapy in subjects that responded to treatment. Preoperatively higher CTCs counts correlated with shortened recurrence-free survival. Taken together, vimentin + CTCs could be a reliable biomarker in pancreatic cancer. The enrichment of mesenchymal CTCs complements the strategy of capturing epithelial CTCs, allowing a more thorough interrogation of the biology and clinical significance of CTCs in PDAC.

KW - Biomarker

KW - CTCs

KW - Epithelial-mesenchymal transition

KW - Pancreatic ductal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85063627074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063627074&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2019.03.009

DO - 10.1016/j.canlet.2019.03.009

M3 - Article

C2 - 30905814

AN - SCOPUS:85063627074

VL - 452

SP - 237

EP - 243

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -